Smithkline Beecham Corporation

Allan R Shatzman

George P Livi

Robert B Kirkpatrick

Lois L Hoyer

Peter R Young

Kyung Oh Johanson

Conrad Gerald Chapman

Helen Elizabeth Clinkenbeard

Kay Elizabeth Murphy

Yen Sen Ho

Michael Joseph Browne

Patrick McDevitt

The present invention provides a method for producing physiologically active human Interleukin-18 ('IL-18').

Method for preparing a physiologically active IL-18 polypeptide

A method for producing a physiologically active polypeptide, comprising contacting a precursor polypeptide with an activating enzyme, or co-expressing the polypeptide with an activating protease.

This invention relates to nucleic acid sequences conserved in strains of yeasts. More particularly, this invention relates to segments of the ALS1 gene of Candida albicans useful as probes and primers for the identification of yeast, particularly Candida, infections.

Conserved yeast nucleic acid sequences

A soluble protein having IL4 and/or IL13 antagonist or partial antagonist activity comprises an IL4 mutant or variant fused to least one human immunoglobulin constant domain or fragment thereof.

Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists

This invention relates to nucleic acid sequences conserved in strains of yeasts. More particularly, this invention relates to segments of the ALSl gene of Candida albicans useful as probes and primers for the identification of yeast, particularly Candida, infections.

Growing community of inventors

King of Prussia, PA, United States of America

Allan R Shatzman